The 5-year recurrence-free probability for patients with cribriform predominant tumors (n=46) was 70%. Patients with adenocarcinoma in situ or minimally invasive adenocarcinoma tumors (n=36) experienced no recurrences (5-year recurrence-free probability, 100%). Patients with lepidic predominant tumors (n=106) had a low risk of recurrence (5-year recurrence-free probability, 92%). Patients with acinar (n=356) and papillary (n=242) predominant tumors had an intermediate risk of recurrence (5-year recurrence-free probability, 87% and 83%, respectively). Patients with micropapillary predominant (n=60), solid predominant (n=139), invasive mucinous (n=44), and colloid predominant (n=9) tumors had a high risk of recurrence (5-year recurrence-free probability, 62%, 70%, 77%, and 71%, respectively).